Nirsevimab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | respiratory syncytial virus fusion protein |
Clinical data | |
Synonyms | MEDI8897 |
ATC code |
|
Identifiers | |
CAS Number | |
UNII | |
Chemical and physical data | |
Formula | C6494H10060N1708O2050S46 |
Molar mass | 146.3 g/mol |
Nirsevimab (MEDI8897) (INN) is a monoclonal antibody designed for the treatment of respiratory syncytial virus.[1][2]
This drug is being developed by MedImmune, LLC.
References
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.